Sagimet Biosciences Inc. (SGMT)

Market Cap	159.37M
Revenue (ttm)	n/a
Net Income (ttm)	-37.52M
Shares Out	32.20M
EPS (ttm)	-1.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	435,365
Open	4.930
Previous Close	5.070
Day's Range	4.920 - 5.250
52-Week Range	2.390 - 20.710
Beta	n/a
Analysts	Buy
Price Target	23.00 (+364.65%)
Earnings Date	Nov 13, 2024

About SGMT

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 14, 2023
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: SGMT
• Website: https://www.sagimet.com

Analyst Forecast

According to 6 analysts, the average rating for SGMT stock is "Buy." The 12-month stock price forecast is $23.0, which is an increase of 364.65% from the latest price.

Price Target

$23.0

(364.65% upside)

Analyst Consensus: Buy